Pulsenmore gets a U.S. route through Ouma, but commercialization still needs numbers

Pulsenmore announced a strategic partnership with Ouma Health, a U.S. telehealth company focused on maternity care. Ouma will integrate Pulsenmore's FDA-authorized home ultrasound platform into its virtual care model, enabling ultrasound monitoring beyond the clinic and in the patient's home. This matters because it connects Pulsenmore's product to a U.S. channel involving clinicians, payers and expectant mothers, rather than only to a regulatory approval. But the filing does not include device volumes, pricing, a revenue model, purchase commitments or a commercial timetable. The right read is therefore that the partnership improves Pulsenmore's U.S. commercialization route, but does not yet prove revenue.

What Ouma adds

Ouma Health is presented as a large independent maternity telemedicine company in the U.S., operating in all 50 states and partnering with payers, health systems, OB groups, community clinics, reproductive agencies and employers. For Pulsenmore, that matters because the problem is not only technology. The product has to enter an existing clinical workflow where providers know who pays, how scans are reviewed and when remote ultrasound complements or replaces an in-person visit.

Pulsenmore notes that 35% of U.S. counties are classified as maternal care deserts. That explains the commercial logic: if home ultrasound can connect remote patients with clinical teams, it may become an important component of hybrid maternity care.

The missing question is who pays and how often it is used

The filing describes technology integration and clinical route, but not the economics. It is not clear whether Ouma buys devices, leases them, pays per use, embeds the service into an existing pricing model, or starts with a pilot that generates data before a broader agreement.

That is especially important for Pulsenmore. In its annual report, the company says revenue remains limited and it recorded losses of NIS 15.9 million, NIS 36.7 million and NIS 58.6 million in 2025, 2024 and 2023, respectively. It also said most product and service revenue in recent years came from customers in Israel, while it expects a substantial percentage of future revenue to come from international markets, specifically the U.S.

The next proof point

The Ouma partnership is positive for market access because it reduces the need for Pulsenmore to build a U.S. clinical network on its own. It also fits a real problem: access to maternity care in underserved regions.

Still, turning the filing into a financial thesis requires numbers. Are there actual deployments? How many devices are delivered? Does Ouma pay upfront or per use? Is reimbursement available? Does usage create recurring revenue or one-time device sales? And does revenue arrive while Pulsenmore's cash position still allows continued investment?

Until those data points appear, the partnership is a positive commercial signal, not proof of sales. If the next quarters show orders, clinical rollout and U.S. revenue, Ouma can become a turning point. If not, it remains another important partnership headline waiting to be converted into usage and money.